Efficacy, Safety, and Correlative Biomarkers of Toripalimab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical Trial (POLARIS-02)

Wang, Feng‐Hua; Wei, Xiaoli; Feng, Jifeng; Li, Qi; Xu, Nong; Hu, Xichun; Liao, Wangjun; Jiang, Yi; Lin, Xiaoyan; Zhang, Qingyuan; Yuan, Xianglin; Huang, Haixin; Chen, Ye; Dai, Guanghai; Shi, Jianhua; Shen, Lin; Yang, Shujun; Shu, Yongqian; Liu, Yunpeng; Wang, Weifeng; Wu, Hai; Feng, Hui; Yao, Sheng; Xu, Rui‐Hua

doi:10.1200/jco.20.02712

Public

Efficacy, Safety, and Correlative Biomarkers of Toripalimab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical Trial (POLARIS-02)

Published in Journal of Clinical Oncology • Jan 25, 2021

Authors:

Feng‐Hua Wang

Xiaoli Wei

Jifeng Feng

Abstract

PURPOSE As yet, no checkpoint inhibitor has been approved to treat nasopharyngeal carcinoma (NPC). This study was aimed to evaluate the antitumor activity, safety, and biomarkers of toripalimab, a new programmed death-1 (PD-1) inhibitor for recurrent or metastatic NPC (RM-NPC) refractory to standard...

Subject

Medicine

Nasopharyngeal carcinoma

Internal medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!